Enteric viruses in HIV-1 seropositive and HIV-1 seronegative children with diarrheal diseases in Brazil

Silvana Augusta Rodrigues Portes1,*, Filipe Anibal Carvalho-Costa1,2, Monica Simões Rocha1, Tulio Machado Fumian1, Adriana Gonçalves Maranhão1, Rosane Maria de Assis1, Maria da Penha Trindade Pinheiro Xavier1, Myrna Santos Rocha3, Marize Pereira Miagostovich1, José Paulo Gagliardi Leite1, Eduardo de Melo Volotão1

1 Laboratory of Comparative and Environmental Virology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil, 2 Escritório Regional Fiocruz Piauí, Teresina, Piauí, Brazil, 3 Hospital Municipal Jesus, Rio de Janeiro, Brazil

* These authors contributed equally to this work.

Sil: sil@ioc.fiocruz.br

Abstract

Diarrheal diseases (DD) have distinct etiological profiles in immune-deficient and immunocompetent patients. This study compares detection rates, genotype distribution and viral loads of different enteric viral agents in HIV-1 seropositive (n = 200) and HIV-1 seronegative (n = 125) children hospitalized with DD in Rio de Janeiro, Brazil. Except for group A rotavirus (RVA), which were detected through enzyme immunoassay, the other enteric viruses (norovirus [NoV], astrovirus [HAstV], adenovirus [HAdV] and bocavirus [HBoV]) were detected through PCR or RT-PCR. A quantitative PCR was performed for RVA, NoV, HAstV, HAdV and HBoV. Infections with NoV (19% vs. 9.6%; p < 0.001), HBoV (14% vs. 7.2%; p = 0.042) and HAdV (30.5% vs. 14.4%; p < 0.001) were significantly more frequent among HIV-1 seropositive children. RVA was significantly less frequent among HIV-1 seropositive patients (6.5% vs. 20%; p < 0.001). Similarly, frequency of infection with HAstV was lower among HIV-1 seropositive children (5.5% vs. 12.8%; p = 0.018). Among HIV-1 seropositive children 33 (16.5%) had co-infections, including three enteric viruses, such as NoV, HBoV and HAdV (n = 2) and NoV, HAstV and HAdV (n = 2). The frequency of infection with more than one virus was 17 (13.6%) in the HIV-1 negative group, triple infection (NoV + HAstV + HBoV) being observed in only one patient. The median viral load of HAstV in feces was significantly higher among HIV-1 positive children compared to HIV-1 negative children. Concerning children infected with RVA, NoV, HBoV and HAdV, no statistically significant differences were observed in the medians of viral loads in feces, comparing HIV-1 seropositive and HIV-1 seronegative children. Similar detection rates were observed for RVA, HAstV and HAdV, whilst NoV and HBoV were significantly more prevalent among children with CD4+ T lymphocyte count below 200 cells/mm³. Enteric viruses should be considered an important cause of DD in HIV-1 seropositive children, along with pathogens more classically associated with intestinal infections in immunocompromised hosts.
Introduction

Diarrheal diseases (DD) represent one of the leading causes of mortality in children, accounting for almost 10% of deaths in this age group [1]. Viruses are among the most frequently enteric pathogens identified in children with DD worldwide [2]. Classic viral enteropathogens include group A rotaviruses (RVA), noroviruses (NoV), astrovirus (HAstV) and enteric adenovirus (HAdV-F). More recently, emerging agents such as bocavirus (HBoV) and Aichi virus (AiV) have been considered as potential etiological agents of DD [3–5].

RVA (Reoviridae family) are the major etiological agents associated with severe DD in children younger than 5 years of age in developed and developing countries [6]. RVA have been classified into 27 G genotypes and 37 P genotypes based on the nucleotide sequences of the VP7 (G-type) and VP4 (P-type) encoded genes. Combinations of G1, G2, G3, G4, G9, and G12 with P[4], P[6] and P[8] have been the most frequently detected in humans [7].

NoV (Caliciviridae family) are responsible for outbreaks and sporadic cases of DD in all age groups, accounting for 50% of all cases and more than 90% nonbacterial DD outbreaks [8]. NoV were classified into seven genogroups (GI to GVII) [9,10]. NoV GI, GII and GIV infect humans, with at least 36 genotypes described so far [8, 11, 12]. The NoV GII is the most frequently detected worldwide, with GII.4 being the most prevalent in DD [10].

HAstV are considered important etiological agents associated with DD in children under 5 years [13]. They belong to family Astroviridae and genus Mamastrovirus (MAstV 1- classical human astrovirus 1–8) and are often detected in children with DD, with HAstV-1 being most commonly detected [14].

HAdV are frequently detected in outbreaks and sporadic DD in children under 5 years [15, 16]. HAdV belong to Adenoviridae family, Mastadenovirus genus and are classified into seven species of HAdV (HAdV-A to -G) with a total of 78 types of HAdV reported. HAdV are associated with different syndromes such as respiratory infections, conjunctivitis and DD. Enteric HAdV-F40 and F41 (species F) are the third most common cause of non-bacterial diarrhea among children. Other species such as A, B, C, G and D have also been detected in DD [17].

Among emerging viral enteric pathogens, HBoV (Parvoviridae family) is a small non-enveloped single-stranded DNA virus identified in 2005 and proposed initially as a putative agent of acute respiratory tract infections [18]. HBoV has also been identified in human stool samples [19] and, in patients with DD, usually present in co-infections with other viral pathogens such as RVA, NoV, and HAstV [20, 21]. Four genotypes have been described: HBoV1 in respiratory samples and HBoV2, HBoV3 and HBoV4 in fecal samples [4, 19, 22].

DD is a very frequent clinical complication and a common cause of hospitalization and death among human immunodeficiency virus 1 (HIV-1) seropositive children [23, 24, 25]. Concerning enteric viruses, different agents have been identified in association with DD in HIV-1 seropositive patients [26, 27, 28, 29]. The positivity for at least one viral agent in HIV-1 seropositive subjects with DD ranges between 6.4% and 52% in distinct surveys carried out in the United States and South America [23, 30, 31, 32].

DD has distinct etiological profiles in immune-deficient and immune-competent patients. In this context it was observed that the detection rate of RVA in children with DD is higher in HIV negative than in HIV positive children in Tanzania [33]. This contrasts with a higher positivity for caliciviruses among HIV-1 positive children when compared to HIV-1 negative children, as described in Venezuela [34].

In HIV-1 positive adults with DD in Brazil, agents such as herpes simplex virus 1 and 2 (HSV-1/2), cytomegalovirus (CVM), HAdV and emerging viruses such as HBoV have been identified; these viruses frequently co-infect patients harboring parasites, including Isospora...
belli, Giardia duodenalis, Strongyloides stercoralis and Entamoeba histolytica/Entamoeba dispar [35].

The objective of this study was to compare detection rates, genotype distribution and viral load of different enteric viral agents in HIV-1 seropositive and HIV-1 seronegative children hospitalized with DD in Rio de Janeiro, Brazil.

**Materials and methods**

**Ethical statement**

This study was approved by the Ethics Committee of the Oswaldo Cruz Foundation (CEP No. 311/06) and is part of an official surveillance of the Brazilian Ministry of Health (MS, Portuguese acronym for Ministério da Saúde) of enteric pathogens to investigate the viral etiology of DD. This surveillance is performed through a hierarchical network in which the samples are provided by medical request in hospitals and health centers, monitored by Unified Health System (SUS, Portuguese acronym for Sistema Único de Saúde). Fecal samples were sent to the Laboratory of Comparative and Environmental Virology (LVCA) of the Oswaldo Cruz Institute (Fiocruz/MS). Records containing epidemiological and clinical data followed each fecal sample. Data are maintained anonymously and securely.

**Setting**

The study was performed in Rio de Janeiro, Brazil (population = 6,300,000 inhabitants). The incidence rate of HIV-1 infection is 41.1 new cases/100,000 inhabitants/year; one of the highest in the country. In Brazil, AIDS incidence in children has reduced substantially following implementation of HIV-1 testing during pregnancy, rapid anti-HIV-1 testing in maternity hospitals and the universal access of exposed newborns to antiretroviral prophylaxis. Children were recruited in two public pediatric hospitals: i) Hospital Municipal Jesus (HMJ), a tertiary pediatric center providing specialized medical care and ii) Hospital Municipal Salles Netto (HMSN), a pediatric general hospital. These hospitals are situated downtown in Rio de Janeiro, 6km distant from each other, providing medical care for children from low and middle socioeconomic status. Identification of enteric viruses was carried out at the LVCA (Fiocruz), 10km from both hospitals.

**Study design, case definition and collection of fecal samples**

We compared 200 fecal samples representing different hospitalizations of 123 HIV-1 seropositive children in HMJ (so that some children [n = 49] were hospitalized more than once) with 125 fecal samples representing hospitalizations of 125 seronegative children (in this group each child was hospitalized once) between the years 1997 and 2010. HIV-1 seropositive and HIV-1 seronegative children were paired by year. The minimum period between hospitalizations was 2 months. Among the 123 HIV seropositive children, 98 (80%) were under highly active antiretroviral therapy (HAART). Among HIV-1 seropositive children, anti-HIV serological status was confirmed through ELISA and/or Western-blot assays. HIV-1 seropositive and HIV-1 seronegative children were matched by age. Age group distribution among HIV-1 seropositive and HIV-1 seronegative children was as follows: i) less than 25 months, 34% (n = 69) and 49.5% (n = 62); ii) 25 to 60 months, 28.6% (n = 57) and 28% (n = 35); more than 60 months, 37.4% (n = 74) and 22.4% (n = 28), respectively. HIV-1 seropositive children were immunocompromised to various degrees; CD4 T lymphocyte count was assessed in 121 HIV-1 seropositive patients: 38 had ≤ 100 cells/mm³, 11 had 100–200 cells/mm³, 13 had 201–350 cell/mm³, 6 had 351–500 cells/mm³ and 53 had > 500 cells/mm³.
Children recruited were participants in a project of DD etiological monitoring conducted in both hospitals during the study period. DD was defined by liquid or semi-liquid stools (with or without fever, vomiting, and abdominal pain) associated with dehydration and the necessity of intravenous fluid replacement. Liquid or semiliquid fecal samples were collected in plastic bottles by health personnel during hospitalization, and stored briefly in the hospital at 4°C until transport to the LVCA, where they were transferred to freezers at -20°C for viral identification.

Statistical analysis

The positivity rates for distinct enteric viruses in HIV-1 seropositive and HIV-1 seronegative children were compared through the Fisher’s exact test (two-tailed). Viral loads among HIV-1 seropositive and HIV-1 seronegative patients, as well as among HIV-1 seropositive children with CD4+ T lymphocyte count below and above 200 cells/mm³ were compared with the Kruskal-Wallis test. Statistical significance was established at p<0.05.

Nucleic acid purification, detection and characterization of enteric viruses

Viral nucleic acids were purified from stool samples stored at -20°C. 140μL fecal suspensions (10%v/v) were prepared in Tris-calcium buffer (Tris/HCl/Ca2+, pH 7.2). The extraction of viral DNA and RNA was performed using the methodology of the QIAamp Viral RNA Mini Kit (QIAGEN®, Valencia, CA, USA). RNA was transcribed to complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Aliquots were immediately stored at -80°C. In each extraction procedure RNase/DNase-free water was used as negative control.

Except for RVA, which were detected through enzyme immunoassay kits (EIARA®, Bio-manguinhos, Rio de Janeiro, Rio de Janeiro, Brazil; Premier Rotaclone®, Meridian Bioscience Inc, Cincinatti, Ohio, USA or Ridascreen Rotavirus®, R-Biopharm, Darmstadt, Hesse, Germany) and polyacrylamide gel electrophoresis (PAGE) [36], and genotyped by semi-nested multiplex reverse transcription polymerase chain reaction (RT-PCR), the other enteric viruses (NoV, HAstV, HAdV and HBoV) were detected through PCR or RT-PCR with sets of primers that amplify specific regions used for viral detection and characterization (Table 1). PCR amplicons were purified using QIAquick Gel Extraction Kit and PCR Purification Kit (Qiagen, Inc., Valencia, CA, USA) following the manufacturer’s recommendations. The purified DNA amplicons were sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit and ABI Prism 3100 Genetic Analyser sequencer (both from Applied Biosystems, Foster City, CA, USA). Sequences were edited and aligned using BioEdit Sequence Alignment Editor Program (Hall, 1999) and subsequently compared to those available in GenBank database using the Basic Local Alignment Search Tool (BLAST). For NoV, genotyping was assigned using an online genotyping tool (http://www.rivm.nl/mpf/norovirus/typingtool) and the strains were named, with the genotype of the polymerase indicated with an uppercase letter p [11,12].

The nucleotide sequences obtained in this study were submitted to the NCBI (GenBank, http://www.ncbi.nlm.nih.gov/) and received accession numbers: KY611586-KY611611; MF150192-MF150203; KY882298-KY882312; KY910901-KY910941; KY753477-753502; MF034109-MF034119; MF034120-MF034125; MF156863-MF156875; MF156863-MF156866; MF156867-MF156875.
Quantification of viral loads

A quantitative PCR (qPCR) was performed for detection and quantification of RVA, NoV, HAstV, HAdV and HBoV according to previously described protocols (Table 1). All qPCR reactions were carried out in an ABI PRISM 7500 Real-Time System v2.0 (Applied Biosystems, Foster City, CA). All assays were performed with TaqMan universal master mix (Applied Biosystems, Foster City, CA). Undiluted and 10-fold dilutions of the nucleic acid and cDNA were analyzed in duplicated and concentrations were estimated as the mean of data obtained, correcting for the dilution analyzed. Amplifications were performed in a thermocycler programmed as follows: incubation at 50˚C for 2 min to activate UNG, initial denaturation at 95˚C for 10 min, followed by 45 cycles at 95˚C for 15s and 60˚C for 1min. The negative control used was a PCR TaqMan master mix without DNA.

Results

Detection rates of enteric viruses and genotype distribution in HIV-1 seropositive and seronegative patients

Among HIV-1 seropositive children, 148/200 (74%) were infected with at least one virus, versus 80/125 (64%) among HIV-1 seronegative children. As presented in Table 2, infections with NoV (19% vs. 9.6%; p<0.001), HBoV (14% vs. 7.2%; p = 0.042) and HAdV (30.5% vs. 14.4%; p<0.001) were significantly more frequent among HIV-1 seropositive children. On the other hand, RVA was significantly less frequent among HIV-1 seropositive patients with DD (6.5% vs. 20%; p<0.001). Similarly, frequency of infection with HAstV was lower among HIV-seropositive children (5.5% vs. 12.8%; p = 0.018).

Table 1. Oligonucleotide primers and probes used for viral detection, quantification and molecular characterization.

| Virus       | Primer | Genomic region | References |
|-------------|--------|----------------|------------|
| RVA<sup>a</sup> | 9con1, 9con2, 9T1-1 (G1), 9T1-2 (G2), 9T1-3P (G3), 9T1-4 (G4), 9T-9B (G9), FT5 (G5) | VP7 | [36,37,38,39,40] |
|             | 4con2, 4con3, 1T1, 1T1-Wa, 1T1-VN P[8], 2T1 P[4], 3T1 P[6], 4T1 P[9], 5T1 P[5] | VP4 | |
| RVA<sup>b</sup> | NSP3F, NSP3R, NSP3P | NSP3 | [41] |
| NoV<sup>a</sup> | Gl: Mon 432, Mon 434 | Region B (polymerase) | [42] |
|             | Gl: Mon 431, Mon 433 |           | |
|             | Gl: Cap A, CapB1, CapB3 | Region D (Capsid) | [43] |
|             | Gl: Cap C, CapD1, CapD3 | ORF1-2 junction | [42,44] |
|             | Gl: Mon431, G2SKR | 5'ORF2 junction | [44,45] |
| NoV<sup>b</sup> | Gl: COG 1, COG1R, RING1cP | ORF1-2 junction | [45] |
|             | Gl: COG 2F, COG2R, RING2P |           | |
| HAstV<sup>a</sup> | Mon 269, Mon 270 | ORF-2 | [46] |
| HAstV<sup>b</sup> | AstVF, AstVR, AstVP | ORF1b-ORF2 junction | [47] |
| HAdV<sup>a</sup> | Hex1deg, Hex2deg | Hexon | [48] |
| HAdV<sup>b</sup> | AdF, AdR, Adp1 | Hexon | [49] |
| HBoV<sup>a</sup> | AK-VP-F1, AK-VP-R1 | VP1/2 | [22] |
|             | Ak-VP-F2, AK-VP-R2 |           | |
| HBoV<sup>b</sup> | HoV1F, HBoV1R, HBoV234F, HBoV 24R, HBoV3R, H1234probe | UTR-NS1 junction | [50] |

A rotavirus (RVA), norovirus (NoV), human adenovirus (HAdV), human astrovirus (HAstV) and human bocavirus (HBoV).

<sup>a</sup>Primes used for molecular detection and characterization.

<sup>b</sup>Primes and probes used for detection and quantification (qPCR).
Table 3 presents genotype distribution of different enteric viruses in HIV-1 seropositive and HIV-1 seronegative patients. It was observed that, among children infected with RVA, G1, G2, G3 and G9 genotypes were detected in HIV-1 seropositive, while G1, G2, G3, G4, G5 and G9 genotypes were in HIV-1 seronegative children. The P[4] and P[8] genotypes were detected in HIV-1 seropositive and seronegative subjects. The combinations G1P[8] and G9P[8] predominated in both groups. Among children in whom NoV was detected, a great diversity of genotypes was observed. Genogroup II was the most frequently identified both in HIV-1 seropositive and HIV-1 seronegative patients, with a predominance of GII.4 and GII.12 in HIV-1 seropositive and GII.4 in HIV-1 seronegative children. GII.4 variants detected were Den Haag_2006b and US95_96 among HIV-1 seropositive children whereas among HIV-1 seronegative children were Kaiso_2003, Asia_2003 and Den Haag_2006b. NoV recombinant genotypes GIL.Pa-GII.3, GIL.P12-GII.10 and GIL.P7-GII.6 were detected among HIV-1 seropositive

Table 2. Enteric virus detection in HIV-1 seropositive children and HIV-1 seronegative children hospitalized with diarrheal diseases by age group in Rio de Janeiro, Brazil.

| Virus/Age group | Fecal samples from 123 HIV-1 seropositive children (n = 200 samples) | Fecal samples from 125 HIV-1 seronegative children (n = 125 samples) | p-value<sup>a</sup> |
|----------------|---------------------------------------------------------------------|------------------------------------------------------------------|------------------|
| **Group A rotavirus** |                                                                 |                                                                 |                  |
| 0–24 months  | 10/69 (14.5%)                                                       | 21/62 (33.9%)                                                   | 0.008            |
| 25–60 months | 0/57 (0%)                                                          | 4/35 (11.4%)                                                    | 0.018            |
| >60 months   | 3/74 (4.1%)                                                        | 0/28 (0%)                                                       | 0.377            |
| Total        | 13/200 (6.5%)                                                      | 25/125 (20%)                                                    | <0.001           |
| **Norovirus** |                                                                 |                                                                 |                  |
| 0–24 months  | 9/69 (13%)                                                         | 5/62 (8.1%)                                                     | 0.263            |
| 25–60 months | 7/57 (12.3%)                                                       | 4/35 (11.4%)                                                    | 0.589            |
| >60 months   | 19/74 (25.7%)                                                      | 3/28 (10.7%)                                                    | 0.081            |
| Total        | 38/200 (19%)                                                      | 12/125 (9.6%)                                                   | 0.033            |
| **Human astrovirus** |                                                              |                                                                 |                  |
| 0–24 months  | 4/69 (5.8%)                                                        | 11/62 (17.7%)                                                   | 0.030            |
| 25–60 months | 3/57 (5.3%)                                                        | 3/35 (8.6%)                                                     | 0.413            |
| >60 months   | 4/74 (5.4%)                                                        | 2/28 (7.1%)                                                     | 0.527            |
| Total        | 11/200 (5.5%)                                                      | 16/125 (12.8%)                                                  | 0.018            |
| **Human bocavirus** |                                                              |                                                                 |                  |
| 0–24 months  | 11/69 (15.9%)                                                      | 5/62 (8.1%)                                                     | 0.133            |
| 25–60 months | 7/57 (12.3%)                                                       | 1/35 (2.9%)                                                     | 0.117            |
| >60 months   | 10/74 (13.5%)                                                      | 3/28 (10.7%)                                                    | 0.497            |
| Total        | 28/200 (14%)                                                      | 9/125 (7.2%)                                                    | 0.042            |
| **Human adenovirus** |                                                              |                                                                 |                  |
| 0–24 months  | 16/69 (23.2%)                                                      | 13/62 (21%)                                                     | 0.463            |
| 25–60 months | 27/57 (47.4%)                                                      | 4/35 (11.4%)                                                    | <0.001           |
| >60 months   | 18/74 (24.3%)                                                      | 1/28 (3.6%)                                                     | 0.011            |
| Total        | 61/200 (30.5%)                                                     | 18/125 (14.4%)                                                  | <0.001           |

<sup>a</sup>Fisher’s exact test.

https://doi.org/10.1371/journal.pone.0183196.t002
Table 3. Genotype distribution of different enteric viruses in fecal samples obtained from 123 HIV-1 seropositive children (n = 200 fecal samples) and 125 HIV-1 seronegative children (n = 125 fecal samples) hospitalized with diarrheal diseases in Rio de Janeiro, Brazil.

| Group A rotavirus genotypes | Fecal samples obtained from HIV-1 seropositive children | Fecal samples obtained from HIV-1 seronegative children |
|----------------------------|--------------------------------------------------------|--------------------------------------------------------|
| G1P[8]                     | 4 (30.8%)                                              | 8 (32%)                                               |
| G2P[4]                     | 3 (23.1%)                                              | 1 (4%)                                                |
| G2P[8]                     | 0 (0%)                                                 | 1 (4%)                                                |
| G3P[NT]                    | 0 (0%)                                                 | 1 (4%)                                                |
| G3P[8]                     | 1 (7.7%)                                               | 0 (0)                                                 |
| G4P[8]                     | 0 (0%)                                                 | 1 (4%)                                                |
| G5P[8]                     | 0 (0%)                                                 | 2 (8%)                                                |
| G9P[8]                     | 5 (38.5%)                                              | 11 (44%)                                              |
| Norovirus genotypes        | n = 38                                                 | n = 12                                                |
| GI (not typed)             | 1 (2.6%)                                               | 1 (8.3%)                                              |
| GI.2                       | 1 (2.6%)                                               | 0 (0%)                                                |
| GI.3                       | 1 (2.6%)                                               | 0 (0%)                                                |
| GII (not typed)            | 6 (15.8%)                                              | 3 (25%)                                               |
| GII.2                      | 3 (7.9%)                                               | 0 (0%)                                                |
| GII.3                      | 1 (2.6%)                                               | 0 (0%)                                                |
| GII.4 US95_96              | 1 (2.6%)                                               | 0 (0%)                                                |
| GII.4 Kaiso_2003           | 0 (0%)                                                 | 3 (25%)                                               |
| GII.4 Asia_2003            | 0 (0%)                                                 | 2 (16.7%)                                             |
| GII.4 Den_Haag_2006b      | 1 (2.6%)                                               | 2 (16.7%)                                             |
| GII.6                      | 3 (7.9%)                                               | 0 (0%)                                                |
| GII.7                      | 0 (0%)                                                 | 1 (8.3%)                                              |
| GII.10                     | 1 (2.6%)                                               | 0 (0%)                                                |
| GII.12                     | 6 (15.8%)                                              | 0 (0%)                                                |
| GII.14                     | 1 (2.6%)                                               | 0 (0%)                                                |
| GII.Pa-GII.3               | 1 (2.6%)                                               | 0 (0%)                                                |
| GII.P4-GII.4               | 1(2.6%)                                                | 0 (0%)                                                |
| GII.P4 US95_96-GII.4      | 1 (2.6%)                                               | 0 (0%)                                                |
| GII.P4-GII.4 US95_96      | 2 (5.3%)                                               | 0 (0%)                                                |
| GII.P7-GII.6              | 4 (10.5%)                                              | 0 (0%)                                                |
| GII.P7-GII.7              | 2 (5.3%)                                               | 0 (0%)                                                |
| GII.P12-GII.10            | 1 (2.6%)                                               | 0 (0%)                                                |
| Human astrovirus genotypes | n = 11                                                 | n = 16                                                |
| 1                          | 10 (90.9%)                                             | 8 (50%)                                               |
| 2                          | 0 (0%)                                                 | 3 (18.7%)                                             |
| 3                          | 0 (0%)                                                 | 2 (12.5%)                                             |
| Not typed                  | 1 (9.1%)                                               | 3 (18.7%)                                             |
| Human bocavirus genotypes  | n = 28                                                 | n = 9                                                 |
| 1                          | 14 (50%)                                               | 6 (66.7%)                                             |
| 2                          | 8 (28.6%)                                              | 1 (11.1%)                                             |
| 3                          | 3 (10.7%)                                              | 1 (11.1%)                                             |
| 4                          | 1 (3.6%)                                               | 0 (0%)                                                |
| Not typed                  | 2 (7.1%)                                               | 1 (11.1%)                                             |

(Continued)
children, with GI.1P7-GI.6 being the most detected. HAstV genotype 1 was the most frequent both in HIV-1 seropositive and HIV-1 seronegative subjects. In HIV-1 seronegative patients, HAstV 2 was the second most detected virus followed by HAstV3. HBoV genotype 1 was the most prevalent in both groups and genotype 2 the second most detected in HIV-1 seropositive children. Among HAdV positive patients, non-enteric species (A, B, C or D) were detected frequently in diarrheic feces from HIV-1 seropositive (25/61 [41%]) and HIV-1-seronegative (9/18 [50%]) children. HAdV D was the second most detected among HIV-1 seropositive children losing only to HAdV- F40. Concerning enteric HAdV types, F40 was detected more frequently than F41 in both groups. All not typed samples presented low viral load by qPCR and failed to attempt genotyping by PCR.

### Multiple viral agents infecting HIV-1 seropositive and HIV-1 seronegative children

As presented in Table 4, 33/200 (16.5%) HIV-1 seropositive patients were excreting more than one enteric virus in fecal samples. In this group, co-infections with three enteric viruses, such as NoV, HBoV and HAdV (n = 2) and NoV, HAstV and HAdV (n = 2) were identified. The rate of infection with more than one virus was 17/125 (13.6%) in the HIV-1 seronegative group, triple infection (NoV + HAstV + HBoV) being observed in only one patient.

### Viral load of enteric viruses in HIV-1 seropositive and HIV-1 seronegative children

As demonstrated in Fig 1, the median viral load of HAstV in feces was significantly higher among HIV-1 seropositive children compared to HIV-1 seronegative children (p = 0.012). Concerning children infected with RVA, NoV, HBoV and HAdV, no statistically significant differences were observed in the medians of viral loads in feces when comparing HIV-1 seropositive and HIV-1 seronegative children. Comparing viral loads of distinct enteric viruses in HIV-1 seropositive patients, it was observed that RVA presented the higher median (5.81 [IQR = 5.53–6.62] log10 copies/g). In this group, median viral load in feces for NoV, HAstV, HBoV and HAdV reached 2.72 (IQR = 0.69–3.51), 1.29 (IQR = 1.17–4.99), 4.72

---

**Table 3. (Continued)**

| Human adenovirus genotypes | Fecal samples obtained from HIV-1 seropositive children | Fecal samples obtained from HIV-1 seronegative children |
|----------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                            | n = 61                                                  | n = 18                                                  |
| A-12                      | 3 (4.9%)                                               | 1 (5.6%)                                               |
| A-31                      | 0 (0%)                                                 | 1 (5.6%)                                               |
| B-3                       | 2 (3.3%)                                               | 0 (0%)                                                 |
| B-7                       | 1 (1.6%)                                               | 2 (11.1%)                                              |
| C-1                       | 2 (3.3%)                                               | 0 (0%)                                                 |
| C-2                       | 6 (9.8%)                                               | 3 (16.7%)                                              |
| C-6                       | 1 (1.6%)                                               | 0 (0%)                                                 |
| D                         | 10 (16.4%)                                             | 2 (11.1%)                                              |
| F-40                      | 30 (49.2%)                                             | 7 (38.9%)                                              |
| F-41                      | 6 (9.8%)                                               | 2 (11.1%)                                              |

https://doi.org/10.1371/journal.pone.0183196.t003
Table 4. Detection of multiple enteric viruses in fecal samples from 123 HIV-1 seropositive children (n = 200 fecal samples) and 125 HIV-1 seronegative children (n = 125 fecal samples) hospitalized with diarrheal diseases in Rio de Janeiro, Brazil.

| No. of viruses | Virus combination in fecal samples | Fecal samples from 123 HIV-1 seropositive children (n = 200 samples) | Fecal samples from 125 HIV-1 seronegative children (n = 125 samples) |
|----------------|------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------|
| Two            | HAsTV + HBoV                       | 1 (0.5%)                                                           | 1 (0.8%)                                                         |
|                | HAsTV + HAdV                       | 4 (2%)                                                            | 3 (2.4%)                                                         |
|                | HBoV + HAdV                        | 6 (3%)                                                            | 0 (0%)                                                           |
|                | NoV + HAsTV                        | 0 (0%)                                                            | 1 (0.8%)                                                         |
|                | NoV + HBoV                         | 5 (2.5%)                                                          | 1 (0.8%)                                                         |
|                | NoV + HAdV                         | 6 (3%)                                                            | 2 (1.6%)                                                         |
|                | RVA + HAsTV                        | 0 (0%)                                                            | 4 (3.2%)                                                         |
|                | RVA + HBoV                         | 3 (1.5%)                                                          | 1 (0.8%)                                                         |
|                | RVA + HAdV                         | 1 (0.5%)                                                          | 2 (1.6%)                                                         |
|                | RVA + NoV                          | 2 (1%)                                                            | 1 (0.8%)                                                         |
|                | Total no. of double infections (%)  | 28 (14%)                                                          | 16 (12.8%)                                                       |
| Three          | HAsTV + HBoV + HAdV                | 1 (0.5%)                                                          | 0 (0%)                                                           |
|                | NoV + HAsTV + HBoV                 | 0 (0%)                                                            | 1 (0.8%)                                                         |
|                | NoV + HAsTV + HAdV                 | 2 (1%)                                                            | 0 (0%)                                                           |
|                | NoV + HBoV + HAdV                  | 2 (1%)                                                            | 0 (0%)                                                           |
|                | Total no. of triple infections (%)  | 5 (2.5%)                                                          | 1 (0.8%)                                                         |

Rotavirus A (RVA), norovirus (NoV), human adenovirus (HAdV), human astrovirus (HAsTV) and human bocavirus (HBoV);

https://doi.org/10.1371/journal.pone.0183196.t004

(IQR = 3.07–4.72), and 3.23 (IQR = 2.27–3.90) log10 copies/g, respectively. RVA also presented the higher median viral load among HIV-1 seropositive children: 6.08 (IQR = 3.36–7.17) log10 copies/g. Among HIV-1 seropositive patients, viral loads in feces were as follows: NoV, 3.36 (IQR = 2.54–4.99), HAsTV, 5.26 (4.18–7.43), HBoV, 3.09 (2–4.31), HAdV, 3.63 (2.27–4.72) log10 copies/g. In HIV-1-seropositive patients, median viral loads of enteric (types F-40 and F-41) and non-enteric (types A-12, A-31, B-3, B-7, C-1, C-2, C-6, and D) HAdV were similar (3.63 [IQR = 2.73–4.53] vs. 3.24 [IQR = 2–5.28], p = 0.210) (not shown).

Fig 1. Fecal viral loads of enteric viruses in HIV-1 seropositive and seronegative children hospitalized with diarrheal diseases in Rio de Janeiro, Brazil.

https://doi.org/10.1371/journal.pone.0183196.g001
Frequency of infection with enteric viruses and viral loads by level of CD4\(^+\) T lymphocyte count

From 200 HIV-1 seropositive, DD-related hospitalizations, we could assess CD4\(^+\) T lymphocyte count in 121 children. From these, 49 had <200 cells/mm\(^3\) and 72 presented a count ≥200 cells/mm\(^3\). It was examined whether among HIV-1 seropositive children, those with a CD4\(^+\) T lymphocyte count below 200 cells/mm\(^3\) had a different enteric virus profile than children with a count above 200 cells/mm\(^3\). Similar detection rates were observed for RVA, HAstV and HAdV, whilst NoV and HBoV were significantly more frequent among children exhibiting a CD4\(^+\) T lymphocyte count below 200 cells/mm\(^3\). Differences in viral loads in both groups were not statically significant for distinct viruses (Table 5).

Discussion

The present study explores the diversity of viral agents in HIV-1 seropositive patients hospitalized with DD, comparing their etiological profile with a group of HIV-1 seronegative children. In this sense, the initial findings were significantly higher NoV, HBoV and HAdV detection rates in the HIV-1 seropositive group. RVA and HAstV were more frequent among HIV-1 seronegative children. In the present study, the opportunistic character of NoV may be evidenced by the fact that, among HIV-1 seropositive children, its positivity rate was more than 3 times higher among patients with CD4\(^+\) T lymphocyte counts <200 cells/mm\(^3\). Despite viral loads being higher among HIV-1 seropositive children, and particularly among those more severely immunocompromised, differences were not statistically significant. In Brazil, NoV has been associated with DD in HIV-1 positive patients [29].

Our results confirm the detection of different genotypes in this group as well as demonstrating the high genetic diversity among HIV-1 seropositive children. Recombinant NoV

Table 5. Rate of detection and fecal viral load of different enteric virus in fecal samples obtained from HIV-1 seropositive children by level of CD4\(^+\) T lymphocyte count in Rio de Janeiro, Brazil.

|                        | CD4 T lymphocytes < 200 cells/mm\(^3\) (n = 49 fecal samples) | CD4 T lymphocytes ≥ 200 cells/mm\(^3\) (n = 72 fecal samples) | P-value |
|------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------|
| **Group A rotavirus**   |                                                               |                                                               |         |
| Rate of detection; No. Positive / No. tested (% positive) | 4 (8.2%)                                                      | 3 (4.2%)                                                      | 0.439a  |
| Median viral load in log10 copies/g (IQR)                | 6.62 (5.81–7.30)                                              | 6.08 (3.63–7.16)                                              | 0.471b  |
| **Norovirus**          |                                                               |                                                               |         |
| Rate of detection; No. Positive / No. tested (% positive) | 18 (36.7%)                                                   | 8 (11.1%)                                                    | 0.001a  |
| Median viral load in log10 copies/g (IQR)                | 3.90 (2.54–4.99)                                              | 2.82 (1.72–5.26)                                              | 0.367b  |
| **Human astrovirus**   |                                                               |                                                               |         |
| Rate of detection; No. Positive / No. tested (% positive) | 0 (0%)                                                       | 4 (5.6%)                                                     | 0.146a  |
| Median viral load in log10 copies/g (IQR)                | -                                                            | 4.72 (3.23–6.62)                                              | -       |
| **Human bocavirus**    |                                                               |                                                               |         |
| Rate of detection; No. Positive / No. tested (% positive) | 12 (24.5%)                                                   | 7 (9.7%)                                                     | 0.041a  |
| Median viral load in log10 copies/g (IQR)                | 3.09 (2.27–4.18)                                              | 2.82 (1.46–5.53)                                              | 0.831b  |
| **Human adenovirus**   |                                                               |                                                               |         |
| Rate of detection; No. Positive / No. tested (% positive) | 13 (26.5%)                                                   | 26 (36.1%)                                                   | 0.321a  |
| Median viral load in log10 copies/g (IQR)                | 3.36 (1.73–4.36)                                              | 4.01 (3.27–4.89)                                              | 0.189b  |

\(^a\)Fisher’s exact test
\(^b\)Kruskal-Wallis test

https://doi.org/10.1371/journal.pone.0183196.t005
circulation has been observed when the combined characterization of both regions of the polymerase and capsid are used. Using both regions we characterized recombinant strains (GII.Pa-GII.3, GII.P12-GII10 and GII.P7-GII.6) for the first time in HIV-1 seropositive children in Brazil. The high genetic diversity of NoV has been described among HIV-1 seronegative individuals [51]. Our data reaffirm that NoV is an important agent of DD in HIV-1 seropositive children in Brazil. NoV has been associated with DD in HIV positive patients, and in some studies it has been detected more frequently in this group, as demonstrated in Tanzania [52]. The importance of NoV as a cause of hospitalization and DD-associated death in HIV-1 seropositive children was also demonstrated in South Africa [53]. In Venezuela it was observed that NoV excretion is significantly more frequent in HIV-1 seropositive children, regardless of whether or not they are suffering from DD [34]. Frequent NoV infection in HIV-1 seropositive children with and without DD has also been reported in Kenya in a study that points to the high genetic diversity of NoV in HIV-1 seropositive children [54].

The present study suggests that HBoV is excreted more frequently in HIV-1 seropositive children than in HIV-1 seronegative children. Cases of HBoV co-infections with other enteric viral agents were common and the most frequent HBoV genotypes identified were 1, 2 and 3. Interestingly, among HIV-1 seropositive children HBoV, like NoV, was significantly more frequent in the group with CD4 T lymphocyte counts <200 cells/mm3. HBoV is an emerging pathogen, considered as a potential DD agent. Its clinical and epidemiological importance as a DD agent has not yet been fully clarified. HBoV has been identified in respiratory secretion of HIV-1 seropositive and HIV-1 seronegative patients with acute respiratory infections [55, 56] and in the feces of HIV-1 seropositive patients in Brazil [35, 57]. Additional studies should be performed to more accurately characterize the role of HBoV as an opportunistic agent in immunocompromised children.

This study demonstrated that HAdV is detected more frequently in HIV-1 seropositive than in HIV-1 seronegative patients and therefore presents an opportunistic behavior. Studies from Brazil report HAdV excretion by HIV-1 seropositive children with and without DD [58]. HAdV is a common cause of pediatric DD, also causing respiratory infections. In immunocompromised patients, other infections, especially CMV, may coexist with HAdV. HAdV associated colitis is a clinical entity characterized by persistent diarrhea described in HIV-1 seropositive patients in the pre-HAART era [26, 27, 59]. For the first time in Brazil, we are reporting enteric HAdV in HIV-1 seropositive patients. In this study, the enteric HAdV type F-40 was detected in almost one-half of HAdV-1 positive fecal samples. However, a great diversity of types was observed, some not commonly associated with DD. Similar viral loads of enteric and non-enteric HAdV were observed, suggesting comparable replication intensity in the digestive tract. Among HIV-1 seropositive children, HAdV was detected with similar frequency and viral load among patients with CD4+ T lymphocyte counts bellow and above <200 cells/mm3.

Results from this study suggest that RVA is a pathogen related neither to HIV-infection, nor to immunodeficiency. RVA is actually a significantly more common pathogen in children with DD hospitalized in a general pediatric hospital with no underlying diseases or complex co-morbidities such as AIDS, as demonstrated in Tanzania [33]. Nevertheless, RVA is also detected in HIV-positive children, particularly among those younger than 24 months. RVA genotype distribution was similar, with predominance of G1P[8] and G9P[8] both in HIV-1 seropositive and HIV-1 seronegative children. RVA is a common cause of DD in pediatric patients, worldwide. In the last decade, its detection rate in children with DD has been reduced due to vaccination with mono- and pentavalent vaccines in countries such as Brazil, where universal vaccination with the monovalent vaccine has been implemented in 2006 [6]. Therefore, in this study, children recruited until 2006 were not vaccinated with the monovalent
rotavirus vaccine. The monovalent rotavirus vaccine is not indicated for immunocompromised HIV-1 seropositive children (CD4⁺ T lymphocyte counts < 200 cells/mm³). From 2006 to 2010, vaccine coverage ranged from 70% to 90% in Rio de Janeiro, for the cohort of children born after March 2006.

H AstV was also more frequent among HIV-1 seronegative children. Despite this, viral load was significantly higher among HIV-1 seropositive children when infected by H AstV, regardless of CD4⁺ T lymphocyte count. H AstV has been detected in HIV-1 seropositive children [31], but its importance as a DD agent in this group has not been established.

Data from this study demonstrate that viral agents are often found in HIV-1 seropositive children hospitalized with DD. As a limitation of this study we highlight the fact of having analyzed children with severe forms of DD, which motivated the hospitalizations, providing an etiological profile of the viral agents in this segment of patients. However, the circulation of enteric viruses in asymptomatic children has been reported, which is important to the DD dynamic of transmission. Thus, enteric viruses should be considered an important cause of DD in this group, along with pathogens more classically associated with intestinal infections in immunocompromised hosts. Management of hospitalized HIV-1 seropositive children with DD should consider enteric viral agents.

Author Contributions

Conceptualization: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Marize Pereira Miagostovich, José Paulo Gagliardi Leite, Eduardo de Mello Volotão.

Data curation: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Monica Simões Rocha, Eduardo de Mello Volotão.

Formal analysis: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa.

Funding acquisition: Marize Pereira Miagostovich, José Paulo Gagliardi Leite, Eduardo de Mello Volotão.

Investigation: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Monica Simões Rocha, Tulio Machado Fumian, Adriana Gonçalves Maranhão, Rosane Maria de Assis, Maria da Penha Trindade Pinheiro Xavier, Eduardo de Mello Volotão.

Methodology: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Monica Simões Rocha, Marize Pereira Miagostovich, José Paulo Gagliardi Leite, Eduardo de Mello Volotão.

Project administration: Eduardo de Mello Volotão.

Resources: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Myrna Santos Rocha, Marize Pereira Miagostovich, José Paulo Gagliardi Leite, Eduardo de Mello Volotão.

Supervision: Filipe Anibalk Carvalho-Costa, Eduardo de Mello Volotão.

Validation: Silvana Augusta Rodrigues Portes, Monica Simões Rocha.

Visualization: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Marize Pereira Miagostovich, Eduardo de Mello Volotão.

Writing – original draft: Silvana Augusta Rodrigues Portes.

Writing – review & editing: Silvana Augusta Rodrigues Portes, Filipe Anibalk Carvalho-Costa, Marize Pereira Miagostovich, José Paulo Gagliardi Leite, Eduardo de Mello Volotão.
References

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 959–987.

2. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2008–15, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2015; 385(9966):430–440. https://doi.org/10.1016/S0140-6736(14)61698-6 PMID: 25280870

3. Clark B, McKendrick M. 2004. A review of viral gastroenteritis. Curr Opin Infect Dis 17(5):461–469.

4. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliffe RM. A novel bocavirus associated with acute gastroenteritis in Australian children. PLoS Pathog. 2009; 5:e1000391. https://doi.org/10.1371/journal. ppat.1000391 PMID: 19381259

5. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliffe RM. A novel bocavirus associated with acute gastroenteritis in Australian children. PLoS Pathog. 2009; 5:e1000391. https://doi.org/10.1371/journal. ppat.1000391 PMID: 19381259

6. Drexler JF, Baumgarte S, de Souza Luna LK, Eschbach-Bludau M, Lukashev AN, Drosten C. Aichi virus shedding in high concentrations in patients with acute diarrhea. Emerg Infect Dis 2011; 17: 1544–1548. https://doi.org/10.3201/e id1708.101556 PMID: 21801647

7. WHO (World Health Organization). Global rotavirus information and surveillance bulletin. Reporting period: January through December 2010. Vol.4. Geneva, Switzerland. 2011.

8. Mesquita JR, Barclay L, Nascimento MS, Vinje J. Novel norovirus in dogs with diarrhea. Emerg Infect Dis. 2010; 16:980–82.

9. Tse H, Lau SK, Chan WM, Choi GK, Woo PC, Yuen KY. Complete genome sequences of novel canine noroviruses in Hong Kong. J Virol. 2012; 86:9531–32. https://doi.org/10.1128/JVI.01312-12 PMID: 22879606

10. Bosch A, Pinto RM, Guix S. Human astroviruses. Clin Microbiol Rev. 2014 27(4):1048–74. https://doi.org/10.1128/CMR.00013-14 PMID: 25278582

11. Krøneman A, Venema H, Deforche K, Avotri HV, Peñasanta S, Osterse MS, et al. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol 2011; 51:121–125. https://doi.org/10.1016/j.j cv.2011.03.006 PMID: 21512143

12. Krøneman A, Vega E, Venema H, Vinje J, White PA, Hansman G, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol. 2013; 158:2059–68. https://doi.org/10.1007/s00705-013-1708-5 PMID: 23615870

13. Bosch A, Pintó RM, Guix S. Human astroviruses. Clin Microbiol Rev. 2014 27(4):1048–74. https://doi.org/10.1128/CMR.00013-14 PMID: 25278582

14. Vu DL, Bosch A, Pintó RM, Guix S. Epidemiology of Classic and Novel Human Astrovirus: Gastroenteritis and Beyond. Viruses. 2017; 9(2).

15. Moyo SJ, Hanevik K, Blomberg B, Kommedal O, Nordba SA, Maselle S, Langeland N. Prevalence and molecular characterisation of human adenovirus in diarrhoeic children in Tanzania; a case control study. BMC Infect Dis. 2014 12; 14:666. https://doi.org/10.1186/s12879-014-0666-1 PMID: 25495029

16. La Rosa G, Della Libera S, Petricca S, Iaconelli M, Donia D, Saccucci P, et al. Genetic Diversity of Human Adenovirus in Children with Acute Gastroenteritis, Albania, 2013–2015. Biomed Res Int. 2015; 2015:142912. https://doi.org/10.1155/2015/142912 PMID: 26339589

17. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp). 2014; 4(1):26–33.

18. Allander T, Tammi MT, Eriksson M, Björkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA. 2005; 102:12891–96 https://doi.org/10.1073/pnas.0504661102 PMID: 16118271

19. Kapoor A, Silkas E, Simmonds P, Chieochansin T, Naem A, Shaikut S, et al. A newly identified bocavirus species in human stool. J Infect Dis. 2009; 199:196–200. https://doi.org/10.1086/595831 PMID: 19072716

20. Lau SK, Yip CC, Que TL, Lee RA, Au-Yeung RK, Zhou B, et al. Clinical and molecular epidemiology of human bocavirus in respiratory and fecal samples from children in Hong Kong. J Infect Dis. 2007; 196:986–93. https://doi.org/10.1086/521310 PMID: 17763318

21. Campe H, Hartberger C, Sing A. Role of Human Bocavirus infections in outbreaks of gastroenteritis. J Clin Virol. 2008; 43:340–42 https://doi.org/10.1016/j.jcv.2008.07.014 PMID: 18835213

22. Kapoor A, Simmonds P, Silkas E, Li L, Bodhidatta L, Sethabutr O, et al. Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis. 2010; 201:1633–43. https://doi.org/10.1086/652416 PMID: 20415538
23. Groome MJ, Madhi SA. Five-year cohort study on the burden of hospitalisation for acute diarrhoeal dis-
24. Arvelo W, Kim A, Creek T, Legwaila K, Puh N, Johnston S, et al. Case-control study to determine risk 
25. Grohmann GS, Glass RI, Pereira HG, Monroe SS, Hightower AW, Weber R, et al. Enteric viruses and 
27. Pollok RC. Viruses causing diarrhoea in AIDS. Novartis Found Symp. 2001; 238:276-83; discussion 
28. Rossit ARB, Gonçalves ACM, Franco C, Machado RLD. Etiological agents of diarrhea in patients 
29. Giordano MO, Martinez LC, Rinaldi D, Espul C, Martinez N, Isa MB, et al. Diarrhea and enteric emerg-
30. Liste MB, Natera I, Suarez JA, Pujol FH, Liprandi F, Ludert JE. Enteric virus infections and diarrhea in 
31. Silva RC, Benati FJ, Pena GP, Santos N. Molecular characterization of viruses associated with gastro-
32. Das BK, Gentsch JR, Cicirello HG, Woods PA, Gupta A, Ramachandran M, et al. Characterization of 
33. Fischer TK, Steinsland H, Molbak K, Ca R, Gentsch JR, Valentiner-Branth P, et al. Genotype profiles of 
34. Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Puustinen L, Vesikari T. One-step quantitative RT-
35. Vinjé J, Hamidjaja RA, Sobsey MD. Development and application of a capsid VP1 (region D) based 
36. Kojima S, Kaheyama T, Fukushima S, Hoshino FB, Shinohara M, Uchida K, et al. Genogroup-specific PCR primers for detection of Norwalk-like viruses. J Virol Methods. 2002; 100: 107-14.
45. Kageyama T, Kojima S, Shinohara M, Uchida K, Fukushi S, Hoshino FB, et al. 2003. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J Clin Microbiol 41(4):1548–1557. https://doi.org/10.1128/JCM.41.4.1548-1557.2003 PMID: 12682144

46. Noel JS, Lee TW, Kurtz JB, Glass RI, Monroe SS. Typing of human astroviruses from clinical isolates by enzyme immunoassay and nucleotide sequencing. J Clin Microbiol. 1995; 33(4):797–801. PMID: 7790440

47. Dai YC, Xu QH, Wu XB, Hu GF, Tang YL, Li JD, et al. Development of real-time and nested RT-PCR to detect astrovirus and one-year survey of astrovirus in Jiangmen City, China. Arch Virol. 2010; 155(6):977–82. https://doi.org/10.1007/s00705-010-0664-6 PMID: 20376681

48. Allard A, Albinsson B, Wadell G. Rapid typing of human adenoviruses by a general PCR combined with restriction endonuclease analysis. J Clin Microbiol 2001; 39:498–505. https://doi.org/10.1128/JCM.39.2.498-505.2001 PMID: 11158096

49. Hernroth BE, Conden-Hansson AC, Rehnstrand-Holm AS, Girónes R, Allard AK. Environmental factors influencing human viral pathogens and their potential indicator organisms in the blue mussel, Mytilus edulis: the first Scandinavian report. Appl Environ Microbiol. 2002; 68(9):4523–33. https://doi.org/10.1128/AEM.68.9.4523-4533.2002 PMID: 12200309

50. Kantola K, Sadeghi M, Antikainen J, Kirveskari J, Delwart E, Hedman K, et al. Real-time quantitative PCR detection of four human bocaviruses. J Clin Microbiol 2010; 48(11):4044–50. https://doi.org/10.1128/JCM.00666-10 PMID: 20844210

51. Fumian TM, da Silva Ribeiro de Andrade J, Leite JP, Migaostovich MP. Norovirus Recombinant Strains Isolated from Gastroenteritis Outbreaks in Southern Brazil, 2004–2011. PLoS One. 2016; 11(4): e0145391. https://doi.org/10.1371/journal.pone.0145391 eCollection 2016. PMID: 27116353

52. Moyo S, Hanevik K, Blomberg B, Kommedal O, Vainio K, Maselle S, et al. Genetic diversity of norovirus in hospitalised diarrhoeic children and asymptomatic controls in Dar es Salaam, Tanzania. Infect Genet Evol. 2014; 26:340–7. https://doi.org/10.1016/j.meegid.2014.06.013 PMID: 24960396

53. Page NA, Groome MJ, Nadan S, Netshikweta R, Keddy KH, Poonam B, et al. Norovirus epidemiology in South African children <5 years hospitalised for diarrhoeal illness between 2009 and 2013. Epidemiol Infect. 2017; 10:1–11.

54. Mans J, Murray TY, Kiulia NM, Mwenda JM, Musoke RN, Taylor MB. Human caliciviruses detected in HIV-seropositive children in Kenya. J Med Virol. 2014; 86(1):75–81. https://doi.org/10.1002/jmv.23784 PMID: 24123055

55. Nunes MC, Kuschner Z, Rabede Z, Madimabe R, Van Niekerk N, Moloi J, et al. Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children. PLoS One. 2014; 9(2):e86648. https://doi.org/10.1371/journal.pone.0086648 PMID: 24488274

56. Garbino J, Inoubli S, Mossdorf E, Weber R, Tamm M, Soccal P, et al.; Swiss HIV Cohort Study. Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. AIDS. 2008; 22(6):701–5. https://doi.org/10.1097/QAD.0b013e3282f470ac PMID: 18356599

57. Santos N, Peret TC, Humphrey CD, Albuquerque MC, Silva RC, Benati FJ, et al. Human bocavirus species 2 and 3 in Brazil. J Clin Virol. 2010; 48(2):127–30. https://doi.org/10.1016/j.jcv.2010.03.014 PMID: 20382557

58. Morillo SG, Lucha A, Cilli A, Carmona RC, Neme SN, Timenetsky MC. Rotavirus genotype G4P[8] and enteric adenovirus in HIV-positive patients with and without diarrhoea in São Paulo State, Brazil. Trans R Soc Trop Med Hyg. 2010; 104(2):165–7. https://doi.org/10.1016/j.trstmh.2009.07.023 PMID: 19729177

59. Yan Z, Nguyen S, Poles M, Melamed J, Scholes JV. Adenovirus colitis in human immunodeficiency virus infection: an underdiagnosed entity. Am J Surg Pathol. 1998; 22(9):1101–6. PMID: 9737243